GT Biopharma, Inc. financial data

Symbol
GTBP on Nasdaq
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 139% % -32%
Debt-to-equity 69% % 49%
Return On Assets -175% % -293%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10,636,135 shares 376%
Common Stock, Shares, Outstanding 6,051,874 shares 171%
Entity Public Float $5,100,000 USD -56%
Common Stock, Value, Issued $6,000 USD 200%
Weighted Average Number of Shares Outstanding, Basic 3,940,714 shares 76%
Weighted Average Number of Shares Outstanding, Diluted 3,940,714 shares 76%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $4,026,000 USD -23%
Operating Income (Loss) $10,590,000 USD 23%
Nonoperating Income (Expense) $1,492,000 USD 5.1%
Net Income (Loss) Attributable to Parent $9,098,000 USD 26%
Earnings Per Share, Basic -3 USD/shares 56%
Earnings Per Share, Diluted -3 USD/shares 56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,528,000 USD -61%
Cash, Cash Equivalents, and Short-term Investments $9,200,000 USD -49%
Assets, Current $4,321,000 USD -36%
Operating Lease, Right-of-Use Asset $27,000 USD -81%
Assets $4,232,000 USD -70%
Accounts Payable, Current $769,000 USD -71%
Accrued Liabilities, Current $400,000 USD -79%
Liabilities, Current $1,321,000 USD -72%
Liabilities $4,600,000 USD -35%
Retained Earnings (Accumulated Deficit) $700,779,000 USD -1.3%
Stockholders' Equity Attributable to Parent $3,000,000 USD 43%
Liabilities and Equity $4,321,000 USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,202,000 USD 47%
Net Cash Provided by (Used in) Financing Activities $616,000 USD
Net Cash Provided by (Used in) Investing Activities $5,034 USD
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 6,051,874 shares 171%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,586,000 USD -282%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,621,000 USD -60%
Deferred Tax Assets, Valuation Allowance $112,184,000 USD 2.3%
Deferred Tax Assets, Gross $112,184,000 USD 2.3%
Operating Lease, Liability $30,000 USD -81%
Lessee, Operating Lease, Liability, to be Paid $30,000 USD -80%
Operating Lease, Liability, Current $30,000 USD -74%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $0 USD -100%
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Additional Paid in Capital $703,772,000 USD 1.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%